Drug Profile
Research programme: acute radiation syndrome radioprotective/radiotherapeutic agents - Medisyn Technologies
Latest Information Update: 15 Jul 2016
Price :
$50
*
At a glance
- Originator Medisyn Technologies
- Developer Humanetics Corporation; Medisyn Technologies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Acute radiation syndrome
Most Recent Events
- 15 Jul 2016 Investigation in Acute radiation syndrome (Prevention) in USA (unspecified route)
- 15 Jul 2016 Investigation in Acute radiation syndrome in USA (unspecified route)